PDF herunterladen
Semin Thromb Hemost 2002; 28(2): 215-226
DOI: 10.1055/s-2002-27823
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Recombinant von Willebrand Factor-Insight into Structure and Function through Infusion Studies in Animals with Severe von Willebrand Disease

Hans Peter Schwarz, Uwe Schlokat, Artur Mitterer, Katalin Váradi, Herbert Gritsch, Eva-Maria Muchitsch, Wilfried Auer, Ludwig Pichler, Friedrich Dorner, Peter L. Turecek
  • Baxter BioScience, Vienna, Austria
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. Mai 2002 (online)

    Lizenzen und Reprints

ABSTRACT

We used a canine and a murine model of von Willebrand disease (vWD) to study the in vivo effects of recombinant von Willebrand factor (vWF). Two preparations were used: (1) a fully processed mature vWF; this was achieved by coexpression of furin. (2) A preparation containing unprocessed pro-vWF, the propeptide still covalently linked to mature vWF. Both preparations induced an increase in canine and murine factor VIII:C (FVIII), which was sustained even when vWF antigen had been removed from the circulation. vWF multimers were analyzed in the plasma samples after infusion using ultra high-resolution 3% agarose gels to allow the separation of homoforms and heteroforms of the vWF polymers. Administration of pro-vWF to dogs with severe vWD resulted in the removal of the propeptide and maturation of vWF in the circulation, indicating that the propeptide cleavage from unprocessed vWF can occur extracellularly. This suggests that the vWF propeptide, besides being derived from the Weibel-Palade bodies of endothelial cells after stimulation, can also be cleaved by pro-vWF in plasma. Using a murine model of vWD, the involvement of the low-density lipoprotein receptor-related protein (LRP) in the clearance of FVIII was established. The low levels of FVIII observed in the absence of vWF are due to an enhanced clearance of FVIII by binding to LRP and removal from the circulation through endocytosis. Administration of the receptor-associated protein (RAP) as a recombinant fusion protein to vWF knockout mice significantly improved the in vivo recovery of recombinant FVIII and the survival time of otherwise rapidly cleared FVIII.

KEYWORD

von willebrand factor - FVIII - canine models - murine knockout models - LRP

REFERENCES

  • 1 Sadler J E, Davie E W. Hemophilia A, hemophilia B, and von Willebrand disease. In: Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H, eds. The Molecular Basis of Blood Diseases 2nd ed. Philadelphia: W.B. Saunders 1995: 657-700
    Google Scholar
  • 2 Sadler J E. von Willebrand factor.  J Biol Chem . 1991;  266 22777-22780
    PubMedGoogle Scholar
  • 3 Sadler J E, Mannucci P M, Berntorp E. Impact, diagnosis and treatment of von Willebrand disease.  Thromb Haemost . 2000;  84 160-174
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 4 Siediecki C A, Lestini B J, Kottke-Marchant K K. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.  Blood . 1996;  88 2939-2950
    PubMedGoogle Scholar
  • 5 Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood . 1996;  87 4223-4234
    CrossrefPubMedGoogle Scholar
  • 6 Ruggeri Z M, Ware J. The structure and function of von Willebrand factor.  Thromb Haemost . 1992;  67 594-599
    PubMedGoogle Scholar
  • 7 Ruggeri Z M. Developing basic and clinical research on von Willebrand factor and von Willebrand disease.  Thromb Haemost . 2000;  84 147-149
    PubMedGoogle Scholar
  • 8 Weiss J H, Sussman I I, Hoyer L W. Stabilization of factor VIII in plasma by the von Willebrand factor.  J Clin Invest . 1997;  60 390-404
    PubMedGoogle Scholar
  • 9 Lenting P J, van Mourik A J, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function.  Blood . 1998;  92 3983-3996
    PubMedGoogle Scholar
  • 10 Vlot A J, Koppelman S J, Bouma B N, Sixma J J. Factor VIII and von Willebrand factor.  Thromb Haemost . 1998;  79 456-465
    PubMedGoogle Scholar
  • 11 Koppelman S J, van Hoeij M, Lankhof H. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C.  Blood . 1996;  87 2292-2300
    PubMedGoogle Scholar
  • 12 Koedam J A, Meijers J CM, Sixma J J, Bouma B N. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor.  J Clin Invest . 1988;  82 1236-1243
    PubMedGoogle Scholar
  • 13 Ginsburg D, Handin R I, Bonthron D T. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization.  Science . 1985;  288 1401-1406
    PubMedGoogle Scholar
  • 14 Kuwano A, Morimoto Y, Nagai T. Precise chromosomal locations of the genes for dentatorubral-pallidoluysian atrophy (DRPLA), von Willebrand factor (F8vWF) and parathyroid hormone-like hormone (PTHLH) in human chromosome 12p by deletion mapping.  Hum Genet . 1996;  97 95-98
    PubMedGoogle Scholar
  • 15 Mancuso D J, Tuley E A, Westfield L A. Structure of the gene for human von Willebrand factor.  J Biol Chem . 1989;  264 19514-19527
    PubMedGoogle Scholar
  • 16 Patracchini P, Calzolari E, Aiello V. Sublocalization of von Willebrand factor pseudogene to 22q11.22-q11.23 by in situ hybridization in a 46,X,t(X;22)(pter ;q1 1.21) translocation.  Hum Genet . 1989;  83 264-266
    PubMedGoogle Scholar
  • 17 Mancuso D J, Tuley E A, Westfield L A. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction.  Biochemistry . 1991;  30 253-269
    CrossrefPubMedGoogle Scholar
  • 18 Sadler J E. Biochemistry and genetics of von Willebrand factor.  Annu Rev Biochem . 1998;  67 395-424
    CrossrefPubMedGoogle Scholar
  • 19 Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(0) structures.  J Biol Chem . 1992;  267 8723-8731
    PubMedGoogle Scholar
  • 20 Matsui T, Shimoyama T, Matsumoto M. ABO blood group antigens on human plasma von Willebrand factor after AB0-mismatched bone marrow transplantation.  Blood . 1999;  94 2895-2900
    PubMedGoogle Scholar
  • 21 Mayadas T N, Wagner D D. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly.  Proc Natl Acad Sci USA . 1992;  89 3531-3535
    PubMedGoogle Scholar
  • 22 Wise R J, Barr P J, Wong P A. Expression of a human proprotein processing enzyme: correct cleavage of the von Willebrand factor precursor at a paired basic amino acid site.  Proc Natl Acad Sci USA . 1990;  87 9378-9382
    PubMedGoogle Scholar
  • 23 van de Ven J M W, Voorberg J, Fontijn R. Furin is a subtilisin-like proprotein processing enzyme in higher eukaryotes.  Mol Biol Rep . 1990;  14 265-275
    CrossrefPubMedGoogle Scholar
  • 24 Vischer U M, Wagner D D. von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies.  Blood . 1994;  83 3536-3544
    CrossrefPubMedGoogle Scholar
  • 25 Wagner D D, Fay P J, Sporn L A. Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.  Proc Natl Acad Sci USA . 1987;  84 1955-1959
    CrossrefPubMedGoogle Scholar
  • 26 Wagner D D, Marder V J. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.  J Cell Biol . 1984;  99 2123-2130
    CrossrefPubMedGoogle Scholar
  • 27 Vischer U M, Ingerslev J, Wollheim C B. Acute von Willebrand factor secretion from the endothelium in vivo: assessment through plasma propeptide (vWF:AgII) levels.  Thromb Haemost . 1997;  77 387-393
    PubMedGoogle Scholar
  • 28 Borchiellini A, Fijnvandraat K, ten Cate W J. Quantitative analysis of von Willebrand factor propeptide release in vivo: Effect of experimental endotoxemia and administration of 1-deamino-8-d-arginine vasopressin in humans.  Blood . 1996;  88 2951-2958
    CrossrefPubMedGoogle Scholar
  • 29 Nichols T C, Samama C M, Bellinger D A. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras.  Proc Natl Acad Sci USA . 1995;  92 2455-2459
    PubMedGoogle Scholar
  • 30 Denis C V, Wagner D D. Insights from von Willebrand disease animal models.  Cell Mol Life Sci . 1999;  56 977-990
    CrossrefPubMedGoogle Scholar
  • 31 Stokol T, Parry B W, Mansell P D. Factor VIII activity in canine von Willebrand disease.  Vet Clin Pathol . 1995;  24 81-90
    PubMedGoogle Scholar
  • 32 Kraus K H, Johnson G S. Von Willebrand's disease in dogs.  Curr Vet Ther . 1989;  10 446-451
    PubMedGoogle Scholar
  • 33 Rieger M, Schwarz H P, Turecek P L. Identification of mutation in the canine von Willebrand factor gene causing type III von Willebrand disease.  Thromb Haemost . 1998;  80 332-337
    PubMedGoogle Scholar
  • 34 Denis C, Methia N, Frenette P S. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis.  Proc Natl Acad Sci USA . 1998;  95 9524-9529
    CrossrefPubMedGoogle Scholar
  • 35 Ni H, Denis C V, Subbarao S. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.  J Clin Invest . 2000;  106 385-392
    CrossrefPubMedGoogle Scholar
  • 36 Sweeney J D, Novak E K, Reddington M, Takeuchi K H, Swank R T. The RIIIS/J inbred mouse strain as a model for von Willebrand disease.  Blood . 1990;  76 2258-2265
    PubMedGoogle Scholar
  • 37 Nichols W C, Cooney K, Mohlke K L. von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene.  Blood . 1994;  83 3225-3231
    PubMedGoogle Scholar
  • 38 Mohlke K A, Purkayastha A A, Westrick R J. MvWF, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase.  Cell . 1999;  96 111-120
    CrossrefPubMedGoogle Scholar
  • 39 Fischer B, Schlokat U, Mitterer A, Den Bouwmeester R, Dorner F. Structural analysis of recombinant von Willebrand factor: identification of hetero- and homo-dimers.  FEBS Lett . 1994;  351 345-348
    CrossrefPubMedGoogle Scholar
  • 40 Fischer B E, Schlokat U, Mitterer A. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin.  FEBS Lett . 1995;  375 259-262
    CrossrefPubMedGoogle Scholar
  • 41 Schwarz H P, Turecek P L, Pichler L. Recombinant von Willebrand factor.  Thromb Haemost . 1997;  78 571-576
    PubMedGoogle Scholar
  • 42 Turecek P L, Gritsch H, Pichler L. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease.  Blood . 1997;  90 3555-3567
    PubMedGoogle Scholar
  • 43 Cameron C, Notley C, Hoyle S. The canine factor VIII cDNA and 5′ flanking sequence.  Thromb Haemost . 1998;  79 317-322
    PubMedGoogle Scholar
  • 44 Rosnoblet C, Ribba A-S, Wollheim C B, Kruithof E KO, Vischer U M. Regulated von Willebrand factor (vWF) secretion is restored by pro-vWF expression in a transfectable endothelial cell line.  Biochim Biophys Acta . 2000;  1495 112-119
    PubMedGoogle Scholar
  • 45 Hop C, Guilliatt A, Daly M. Assembly of multimeric von Willebrand factor directs sorting of P-selectin.  Arterioscler Thromb Vasc Biol . 2000;  20 1763-1768
    PubMedGoogle Scholar
  • 46 Mourik J A, Boertjes R, Huisveld I A. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation.  Blood . 1999;  94 179-185
    PubMedGoogle Scholar
  • 47 Sporn L A, Marder V J, Wagner D D. Inducible secretion of large, biologically potent von Willebrand factor multimers.  Cell . 1986;  46 185-190
    CrossrefPubMedGoogle Scholar
  • 48 Turecek P L, Pichler L, Auer W. Evidence for extracellular processing of pro-von Willebrand factor after infusion in animals with and without severe von Willebrand disease.  Blood . 1999;  94 1637-1647
    PubMedGoogle Scholar
  • 49 Furlan M, Robles R, Affolter D, Meyer D, Baillod P. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers.  Proc Natl Acad Sci USA . 1993;  90 7503-7507
    PubMedGoogle Scholar
  • 50 Furlan M, Robles R, Galbusera M. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med . 1998;  339 1578-1584
    CrossrefPubMedGoogle Scholar
  • 51 Takagi J, Aoyama T, Ueki S. Identification of factor-XIIIa-reactive glutaminyl residues in the propolypeptide of bovine von Willebrand factor.  Eur J Biochem . 1995;  232 773-777
    CrossrefPubMedGoogle Scholar
  • 52 Takagi J, Sekija F, Kasahara K, Inada Y, Saito Y. Inhibition of platelet-collagen interaction by propolypeptide of von Willebrand factor.  J Biol Chem . 1989;  264 6017-6020
    PubMedGoogle Scholar
  • 53 Isobe T, Hisaoka T, Shimizu A. Propolypeptide of von Willebrand factor is a novel ligand for very late antigen-4 integrin.  J Biol Chem . 1997;  272 8447-8453
    CrossrefPubMedGoogle Scholar
  • 54 Muchitsch E-M, Turecek P L, Zimmermann K. Phenotypic expression of murine hemophilia.  Thromb Haemost . 1999;  82 1371-1373
    PubMedGoogle Scholar
  • 55 Vlot A J, Koppelman S J, Meijers J CM. Kinetics of factor VIII von Willebrand factor association.  Blood . 1996;  87 1809-1816
    CrossrefPubMedGoogle Scholar
  • 56 Bu G. Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family.  Curr Opin Lipidol . 1998;  9 149-155
    PubMedGoogle Scholar
  • 57 Neels J G, Horn I R, van den Berg M M B, Pannekoek H, van Zonneveld J A. Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multi-ligand endocytic receptor.  Fibrinolysis Proteolysis . 1998;  12 219-240
    PubMedGoogle Scholar
  • 58 Warshawsky I, Bu G, Schwartz A L. 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.  J Clin Invest . 1993;  92 937-944
    PubMedGoogle Scholar
  • 59 Narita M, Bu G, Olins G M. Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vitro.  J Biol Chem . 1995;  270 24800-24804
    CrossrefPubMedGoogle Scholar
  • 60 Narita M, Rudolph A E, Miletich J P, Schwartz A L. The low-density lipoprotein receptor-related protein (LRP) mediates clearance of coagulation factor Xa in vivo.  Blood . 1998;  91 555-560
    PubMedGoogle Scholar
  • 61 Lenting P J, Neels J G, van den Berg M M B. The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.  J Biol Chem . 1999;  274 23734-23739
    CrossrefPubMedGoogle Scholar
  • 62 Turecek P L, Lenting P J, Binder B, Mihaly J, Schwarz H P. Improvement of recovery and prolongation of half-life of factor VIII.  Haemophilia (Abst) . 2000;  6 355
    PubMedGoogle Scholar
  • 63 Turecek P L, Binder B R, Schwarz H P. In vivo inhibition of low density lipoprotein receptor-related protein (LRP) improves survival of factor VIII in the absence of von Willebrand factor.  Blood . 2000;  95 3637-3638
    PubMedGoogle Scholar
  • 64 Schwarz H P, Lenting P J, Binder B. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice.  Blood . 2000;  95 1703-1708
    PubMedGoogle Scholar